Premium
Vemurafenib‐induced granulomatous hepatitis
Author(s) -
Spengler Erin K.,
Kleiner David E.,
Fontana Robert J.
Publication year - 2017
Publication title -
hepatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.488
H-Index - 361
eISSN - 1527-3350
pISSN - 0270-9139
DOI - 10.1002/hep.28692
Subject(s) - vemurafenib , medicine , rash , melanoma , hepatitis , dermatology , gastroenterology , cancer research , metastatic melanoma
Vemurafenib (Zelboraf; Genentech, CA) is a highly effective oral chemotherapy agent for patients with metastatic melanoma who carry the BRAF V600E mutation. Side effects of this protein kinase inhibitor (PKI) include arthralgia, rash, and fatigue, which are reported in up to one third of treated patients. Mild abnormalities in liver biochemistries were reported with vemurafenib use in 30% of subjects, 11% developed severe laboratory abnormalities, and acute liver failure has been reported (Table [Table 1. Hepatotoxicity of Approved Protein Kinase Inhibitors]). Herein, a case of severe vemurafenib‐induced granulomatous hepatitis leading to chronic cholestasis is reported along with a review of the hepatotoxicity of other PKIs.